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Stlmmal'y 
Major histocompatibility complex (MHC)-restricted cytotoxic T  lymphocytes (CTL) are part 
of the cellular immune response to human persistent virus infections. Measurements of the frequency 
and specificity of human immunodeficiency  virus type I (HIV-1)-specific CTL and their variation 
with time may indicate their relative importance in modulating the progression of HIV-1 infection. 
We have used limiting dilution analysis (LDA) to derive quantitative estimates of the frequency 
of HIV-l-specific  CTL precursors  in a cross-sectional  study of 23 patients at different clinical 
stages of HIV-1 infection and to compare these with the frequency of CTL precursors  specific 
for another persistent virus (Epstein-Barr  virus [EBV]) in the same patients. Peripheral blood 
mononuclear cells (PBMC) were stimulated in vitro with autologous HIV-l-infected lymphoblasts 
and assayed for cytotoxicity in SlCr release assays against autologous and MHC-mismatched 
lymphoblastoid B cells infected with recombinant vaccinia viruses expressing the three HIV-1 
structural gene products. The frequency of MHC-restricted precursors was high in asymptomatic 
HIV-l-infected patients (env-specific CTL precursors  up to 73/106 PBMC;  gag-specific CTL 
precursors up to 488/106 PBMC), although the relative frequency against the different structural 
gene products varied from patient to patient. The HIV-l-specific CTL precursor frequency was 
reduced in patients who had more severe (<400//~1) CD4 § lymphocyte depletion, while in the 
majority of such patients the frequency of CTL precursors against EBV was maintained at levels 
observed in healthy controls. Direct CTL activity in unstimulated PBMC was observed in three 
of nine patients but no correlation was found between the presence of an activated CTL response 
and the magnitude of the CTL response detected after stimulation in LDA. Thus, CTL precursors 
were  detected  against  all  three  HIV-1  structural  gene  products  in  patients  with  CD4 § 
lymphocyte counts >400//~1, at frequencies that are high compared with those reported for other 
persistent viruses. A CTL response directed against multiple protein antigens of HIV-1 may protect 
the patient against epitope variation. The fact that the EBV-specific CTL precursor frequencies 
were maintained in advanced HIVol infection suggests that there may be selective impairment 
of the HIVol-specific CTL response associated with disease progression. 
T 
he immune response to HIV infection has been exten- 
sively studied and the antibody response against the virus 
has been characterized  in detail.  Because of the capacity of 
the virus to spread in cells, there has been increasing interest 
in the role of cell-mediated immunity, and in particular MHC- 
restricted CTL in HIV-1 infection (1). These are effector T 
cells that are able to kill virus-infected cells through recogni- 
tion of viral protein antigens that have been processed within 
the infected cell into short peptide fragments and transported 
to the cell surface and presented in association with MHC 
molecules. Virus-specific CTL have been shown to play a role 
in the clearance of acute infections and in the control of per- 
sistent virus infections in animal models (2, 3) and in humans 
(4,  5). 
HIV-l-specific CTL have previously been detected in HIV- 
1-infected patients at different clinical stages of infection and 
at different sites, including peripheral blood, cerebrospinal 
fluid (6), and bronchoalveolar lavage fluid (7). In such studies, 
HIV-l-specific  CTL have been shown to recognize antigens 
derived from the major viral structural gene products (env, 
gag, pol) and also from some of the nonstructural regulatory 
gene products (nef, vif, rev) (1). In a proportion of asymp- 
249  J. Exp.  Med.  ￿9  The Rockefeller  University Press ￿9 0022-1007/93/02/0249/08 $2.00 
Volume  177  February  1993  249-256 tomatic HIV-l-infected patients, activated HIV-l-specific CTL 
can be detected directly in unstimulated PBMC without sec- 
ondary in vitro stimulation. This is unusual since detection 
of virus-specific CTL in other asymptomatic persistent virus 
infections normally requires in vitro stimulation with antigen. 
The fine antigen specificity and MHC-restricting alleles for 
different HIV-l-specific  CTL clones have been defined (1). 
CDS-positive T  lymphocytes have also been shown to in- 
hibit the replication of HIV-1 in vitro by a mechanism inde- 
pendent of direct cellular cytotoxicity (8). 
The relative importance of the HIV-l-specific CTL response 
compared with other components of the immune response 
in restraining viral replication during asymptomatic HIV-1 
infection and the subsequent progression to AIDS is unclear. 
Quantitative information regarding the HIV-l-specific  CTL 
response might help to define its contribution to the immune 
response; knowledge of the relative frequency of CTL against 
different HIV-1 gene products and their fine antigen specificity 
would assist the rational development of vaccines capable of 
inducing an effective CTL response. However in contrast to 
the antibody response against HIV-1, to date little quantita- 
tive information is available regarding the HIV-l-specific CTL 
response.  This paucity of information reflects the consider- 
able technical difficulty  in measuring the number of antigen- 
specific effector T cells; the principal technique that has been 
used  is  limiting dilution  analysis  (LDA)  1 (7,  8,  10,  11). 
Hoffenbach et al. (7) studied the env-specific CTL response 
in LDA, using as target cells the mouse plasmacytoma cell 
line P815 stably transfected with both human MHC class 
I A2 and the env gene of HIV-BRU. In four asymptomatic 
HIV-l-infected patients, the env-specific CTL precursor fre- 
quency was between 270 and 2,000/106  PBMC. In one pa- 
tient there was a decline in CTL precursor frequency over 
a 6-too period before the patient developed AIDS. Gotch et 
al. (10) studied gag-specific CTL in three asymptomatic HIV-1- 
infected hemophiliacs, and defined the CTL epitope within 
gag p24 with synthetic peptides.  The frequency of peptide- 
specific  CTL  precursors  was  between  120  and  280/106 
PBMC. 
In our previous studies applying LDA to studies of human 
herpes virus-specific CTL (12, 13), we developed automated 
methods (14) to quantify virus-specific  CTL precursors  in 
larger numbers of patients than has previously been possible. 
Here we report our quantitative analysis of the CTL response 
directed against each of the HIV-1 structural gene products, 
env, gag, and pol, compared with the CTL response against 
another persistent virus, EBV, in a cross-sectional  study of 
23 patients at different stages of HIV-1  infection. 
Materials and Methods 
Patients.  23 adult patients (19 males, 14 females)  were recruited 
at different clinical stages of HIV-1 infection as assessed by clinical 
features and CD4 + lymphocyte counts. 18 were Center for Dis- 
ease Control (CDC) stage II, including six who had CD4 + lym- 
phocyte counts in the normal range (530-2,200//~1), one patient 
was CDC stage IVa, three were CDC stage IVcl, and one was CDC 
1 Abbreviation used in this paper: LDA, limiting dilution analysis. 
stage IVd. HIV-1 infection was acquired through intravenous drug 
use in eight, male homosexuality in 11, heterosexuality in three, 
and through blood products in one patient. All were seropositive 
for HIV-1 by both ELISAs (Serodia; Fujirebio Inc., Tokyo,  Japan) 
and peptide blotting (Liatek; Organon,  Teknika, Holland), and 
positive for anti-EBV IgG by indirect immunofluorescence on 
acetone-fixed  EBV-infected  HKIK cells. EBV-transformed  lympho- 
blastoid B cell lines from each subject were established  by standard 
methods using B95.8 virus (type 1 isolate); all were free of myco- 
plasma contamination by DNA staining. MHC class I tissue typing 
was performed using serological  lymphocytotoxicity plates (Lym- 
photype ABC-120; Biotest, Frankfurt, Germany). All subjects un- 
derwent clinical and hematological assessment every 3-6 mo. In 
addition, seven healthy laboratory workers (three males, four fe- 
males) at low risk of HIV-1 infection were studied as controls. 
Recombinant Vaccinia Viruses.  Recombinant vaccinia  viruses ex- 
pressing specific HIV-1 gene products were grown on Veto cells 
that were harvested, sonicated, and plaqued on Veto cells (titer, 
2.0  x  107 to 10  s 50% tissue culture infectious doses [TCIDs0]/ 
ml). Cell-associated  viruses were stored in 1-ml aliquots at -70~ 
and sonicated before use. The recombinant vaccinia viruses used 
were vac env (expressing env gp160 5515-8375 of HIV-IIIB; M. 
Mackett, Manchester, UK), vac gag (expressing gag p55 1-1871 
of HIV-IIIB; M. Mackett), vac pol (expressing pol p105 of HIV- 
BKU; M. Kieny,  Transgene, Strasbourg, France), and, as a nega- 
tive control expressing an irrelevant protein, vac T7 (expressing 
bacteriophage T7 KNA polymerase; B. Moss, Bethesda, MD), all 
made available through the MRC AIDS Directed Programme Re- 
agent Project. 
Limiting  Dilution  Analysis.  LDA is an in vitro technique by 
which the CTL response can be analyzed at the level of the in- 
dividual responding cell. By growing a large number of short-term 
CTL clones, it is possible to derive  quantitative  estimates  of  antigen- 
specific CTL precursors (9). PBMC were prepared from fresh 
heparinized venous  blood samples by Ficoll-Hypaque  (Lymphoprep; 
Nyegaard, Oslo, Norway) density gradient centrifugation. Repli- 
cate microcultures (n = 27) of fresh PBMC were set up in 96-well 
round-bottomed  plates (Linbro; Flow Laboratories  Ltd., Irvine, Scot- 
land) in which the number of PBMC per well was progressively 
reduced over an appropriate  range of  dilutions in RPMI 1640 (Flow 
Laboratories Ltd.) supplemented  with 10% (vol/vol)  myoclone  plus 
FCS (Gibco Laboratories,  Grand Island, NY), 2.0 mM L-glutamine, 
10  s IU/liter of penicillin, and 100 rag/liter of streptomycin (Flow 
Laboratories). 
HIVl.specific CTL Precursors.  Fresh  autologous PBMC were su- 
perinfected  with HIV-IIIB (MOI, 1:100) for 4 h at 37~  in medium 
supplemented  with 4 #g/ml PHA (unpurified  PHA-P; Sigma  Chem- 
ical Co., Poote, UK), washed three times in PBS, and irradiated 
(2,400 rad). 2  ￿  104 of these autologous lymphobhsts were added 
to each well as APC/feeder cells, with human rlL-2 (MRC AIDS 
Directed Programme)  in medium at a final  concentration  of 5 IU/ml 
and a final volume of 100/zl. The cultures were incubated at 37~ 
in 5% CO2 and were refed with medium supplemented with 5 
IU/ml Ib2 on days  5 and 9. On day 15, the cells in each individual 
well were resuspended and divided into four aliquots that were as- 
sayed for cytotoxicity in 6-h SlCr release assays against 4  x  10  3 
autologous or MHC-mismatched  target cells. These comprised  lym- 
phoblastoid  B cell  lines that had been infected  for 12 h with different 
recombinant vaccinia  viruses (10 TCIDs0/cell), incubated with ra- 
dioactive chromium SICr (Amersham Corp., Arlington Heights, 
IL) (100/~Ci/2  x  104 cells) for 1 h at 37~  and washed four 
times in medium. On each plate six wells with target cells only 
were incubated  with aqueous 2% triton-X (Merck  Ltd., Poole, UK) 
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added to six wells on each plate containing irradiated feeder cells 
previously cultured without responder cells to determine sponta- 
neous release. Spontaneous release was <30% of maximum release 
in all experiments. After incubation for 6 h at 37~  culture super- 
natants were harvested and the radioactivity counted using a gamma 
counter (Cobra 5010; Hewlett-Packard Co., Meriden, CT). The 
assays were automated using a computer-controlled robotic processor 
(Biomek 1000 Automated Laboratory Workstation; Beckman In- 
struments,  Inc., Palo Alto, CA) (14). 
EBV-sI~cific CTL Precursors.  Replicate dilutions of fresh PBMC 
were set up as described above from the same blood samples. As 
APC/feeder cells, 5  x  10  ~ autologous irradiated (2,400 tad) lym- 
phobhstoid B cells were added to each well in medium supplemented 
with 5 IU/ml Ib2 final concentration in a final volume of 100 #1. 
The cultures were refed on days 5 and 9 as above. On day 14 the 
cells in each well were resuspended and divided into four aliquots 
that were assayed for cytotoxicity against 4  x  10  ~ SlCr-labeled au- 
tologous or MHC-mismatched lymphoblastoid B cells in a 6-h 
SlCr release assay. 
Analysis.  Each individual well was regarded as positive for cy- 
totoxicity when the S~Cr release exceeded a defined threshold. In 
previous studies using LDA, a threshold for each target cell type 
equal to the mean plus 3 SD of radioactivity release in control wells 
(containing irradiated feeder cells only) has been used (7, 11, 15). 
However, the threshold calculated this way varies from one target 
cell type to another over a range equivalent to 3-13% of specific 
S~Cr release, which alters the sensitivity of the assay between au- 
tologous and mismatched targets and between experiments, and 
which can adversely affect the linearity of the LDA plots. In our 
experiments, the distribution of MHC-restricted SlCr release from 
limiting dilution cultures was biomodal, as expected from wells 
that contain either no precursors or at least  one precursor (16); 
from this bimodal distribution the threshold that consistently dis- 
tinguished  between  wells  lacking  a  precursor or containing  a 
precursor was 10% specific lysis (Carmichael et al., manuscript in 
preparation).  Therefore, all experiments were analyzed using a 
threshold of 10% specific lysis, i.e., spontaneous release +  0.1 (max- 
imum release -  spontaneous release) for that target cell type, which 
had the advantage of  standardizing  the sensitivity in all experiments. 
Because we used split-well  analysis for each target cell type in 
every experiment, it was possible to identify wells with non-MHC- 
restricted cytotoxicity (killing  of both  autologous  and  MHC- 
mismatched target cells) that were excluded from further analysis. 
Limiting dilution plots for MHC-restricted killing were produced 
by plotting the proportion of negative wells against  the initial re- 
sponder cell number per well on a semilogarithmic plot. Provided 
the single-hit Poisson model (9) was fulfilled (a straight line rela- 
tionship demonstrated by the X  2 value for goodness of fit), the 
regression line was calculated by the maximum likelihood method 
(17). From the single-hit Poisson model, the frequency of antigen- 
specific MHC-restricted CTL precursors was estimated from the 
initial responder cell number at which 37% of the wells were nega- 
tive for cytotoxicity. Calculations were performed using Statistical 
Package for Social Sciences/Personal  Computer  +  (SPSS/PC)  + 
V2.0 (SPSS Inc., Chicago, IL) and GLIM 3.77 (Royal Statistical 
Society, London, UK), and the estimates of CTL precursor fre- 
quency and  95%  confidence intervals  were  expressed  per  106 
PBMC. 
Direct Cytotoxicity Assays.  Unstimulated fresh PBMC, from the 
same samples used to determine the CTL precursor frequency, were 
plated on 96-well round-bottomed plates at five E/T ratios (from 
1.6:1 to 100:1) in triplicate, and assayed for cytotoxicity in 6-h SlCr 
release assays against  4  x  103 autologoas and MHC-mismatched 
target cells infected with recombinant vaccinia viruses expressing 
specific HIV-1 gene products as described above. Spontaneous re- 
lease was determined from six replicate wells containing medium 
only; maximum release was determined from three replicate wells 
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Figure  1.  Simultaneous  determination of the fre- 
quency of CTL precursors  against env, gag, and pol 
using LDA. Fresh PBMC from an asymptomatic HIV- 
1-infected patient were cocultured with autologous ir- 
radiated HIV-IIIB-inffcted lymphoblasts and IL-2 as 
described.  On day 15, the cultures were assayed for 
cytotoxicity against autologous and MHC-mismatched 
lymphoblastoid B cell lines infected with recombinant 
vaccinia viruses expressing individual structural gene 
products of HIV-IIIB and negative control T7 RNA 
polymerase. Limiting dilution plots of MHC-restricted 
killing are only plotted with the regression  line and 
its 95% confidence intervals (calculated by the method 
of ma.~dmum likelihood). The CTL precursor fzequency 
is estimated from the intercept of the regression line 
at 37%  negative wells:  env-specific CTLp  (73/106 
PBMC), gag-specific CTLp (225/10  ~ PBMC), pol- 
specific  CTLp  (36/106  PBMC),  negative  control 
(3/10  6 PBMC). A 
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Figure  2.  In the cross-sectional analysis, the fre- 
quency of HIV-1 specific CTL precursors was reduced 
in  HIV-l-infected patients  who  had  more  severe 
CD4 § lymphocyte  depletion.  For each patient,  the 
CTL precursor frequencies (with 95% confidence in- 
tervals) against target  cells expressing env, gag, pol, 
and negative  control T7 are plotted against the pa- 
tient's CD4 + lymphocyte count decreasing from left 
to right as an index of the progression of HIV-1 infec- 
tion, (Filled symbols)  HIV-1-infected patients. (Open 
symbols)  Healthy controls. 
to which aqueous 2% triton-X was added. The percent specific 
lysis was calculated as follows: 100x  (test release -  spontaneous 
release)/(maximum release -  spontaneous release). The difference 
between the percent specific lysis of autologous and mismatched 
target cells at an E/T ratio of 50:1 was assessed by student's t test; 
differences where p  <0.05  were considered  significant. 
Results 
Frequency of HIVl-specific CTL Precursors.  62 of the  74 
experiments yielded linear LDA plots (Fig.  1). The frequency 
of env-specific  CTL  precursors  was  0-73/106  PBMC,  for 
gag-specific  CTL precursors, 0-488/106 PBMC, and for pol- 
specific  CTL  precursors,  0-93/106  PBMC  (Fig.  2, filled 
symbols). After in vitro stimulation of PBMC in LDA, three 
healthy HIV-l-uninfected controls showed only strong non- 
MHC-restricted cytotoxic responses against all target cell types. 
Three other controls  showed low responses  that were not 
HIV-1  specific  (Fig.  2, open symbols). 
Frequency of  EBV-specific CTL Precursors.  The EBV-specific 
CTL response was studied in LDA in 20 patients. In seven 
experiments the frequency of EBV-specific  CTL precursors 
could not be estimated either because of very high levels of 
non-MHC-restricted  killing  (which made it impossible  to 
identify any underlying MHC-restricted CTL activity)  or be- 
cause the LDA plot was nonlinear.  In the remaining patients, 
the EBV-specific CTL precursor frequency was between 2 and 
579/106  PBMC. 
Relation between CTL Precursor  Frequency  and Stage of HIV-1 
Infection.  In the cross-sectional  analysis of the CTL precursor 
frequency according to the stage of HIV-1 infection in the 
patient cohort,  the CTL precursor  frequency was reduced 
in patients  who had more severe (<400//d)  CD4 § lympho- 
cyte depletion.  In contrast,  in six of eight  patients  whose 
CD4 +  lymphocyte  count  was  <400/pl,  the frequency of 
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Figure  3.  The frequency of EBV-specific CTL precursors may be main- 
tained in advanced HIV-1 infection.  Fresh PBMC  from HIV-1 infected 
patients (filled symbols) and healthy controls (open symbols) were cocultured 
with autologous irradiated EBV-transformed lymphoblastoid  B cells and 
IL-2 as described. On day 14, cultures were assayed  for cytotoxicity against 
autologous  and MHC-mismatched lymphoblastoid  B cells, and the fre- 
quency of MHC-restricted  CTL precursors was plotted against the CD4 § 
lymphocyte count. In six of the HIV-1 infected patients whose CD4 + 
lymphocyte count was <400/~l and whose HIV-1 specific response was 
very low or undetectable (top), EBV-specific CTL precursors were detected 
at frequencies that are observed in healthy  controls (bottom). 
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Cytotoxic activity in unstimulated PBMC* 
CTL  precursor frequency*  ENV  GAG  POL  T7 
CD4 + 
Patient  count  ENV  GAG  POL  T7  aut  mis  nut  mis  aut  mis  nut  mis 
per/~I 
1  680  72  58  _s  _  9.3  11.9  1.7  8.8  2.2  14.8  1.5  11.9 
2  570  47  22  7  25  4.0  0.0  4.2  0.0  0.0  0.1  0.0  1.6 
3  510  7  5  6  5  1.5  0.7  5.2  0.1  1.9  0.0  0,0  1.3 
4  450  17  489  93  -  9.8  13.7  10.8  9.4  5.8  6.4  6.0  8.6 
5  420  73  110  23  6  10.6  6.2  8.7  4.7  7.0  6.7  3.4  8.9 
6  280  4  13  1  1  0.0  0.0  1.9  0.0  0.6  0.0  ND 
7  210  15  9  12  3  7.1  14.1  2.6  5.4  10.3  0.0  3.8  7.3 
8  140  9  21  54  8  13.0  4.9  13.4  2.9  11.0  5.8  7,1  3.2 
9  50  0  0  1  0  7.8  11.3  0.0  4.7  2.9  5.3  4.3  5.2 
* Expressed per  106 PBMC  using threshold  of control plus  10%  specific release. 
t Percent specific lysis at E/T ratio of 50:1 against autologous (nut) and MHC mismatched (mis) target cells. Results that show significant (p <  0.05) 
greater  killing of autologous  targets  compared with mismatched  targets  are underlined. 
S Indicates that LDA plot was nonlinear. 
CTL precursors against EBV remained equal to or higher 
than that observed in healthy control subjects  (Fig.  3). 
Direct Cytotoxicity Assays.  MHC-restricted CTL in un- 
stimulated PBMC were detected in three of the nine patients 
studied (Table 1). In patient 8, activated MHC-restricted CTL 
specific for env (Fig. 4 a) and for gag were detected; the cor- 
responding env- and gag-specific CTL precursor frequencies 
in LDA were 9/106 PBMC and 21/106 PBMC. In patient 
7, activated MHC-restricted CTL were detected against target 
cells expressing pol (Fig. 4 b); the corresponding pol-specific 
CTL precursor frequency in LDA was 12/106 PBMC. In pa- 
tient 5, activated MHC-restricted CTL were detected against 
target cells expressing gag (Fig. 4 c); the corresponding gag- 
specific  CTL  precursor  frequency  in  LDA  was  110/106 
PBMC. Non-MHC-restricted killing of both autologous and 
MHC-mismatched target cells was observed in several pa- 
dents, and this may have obscured the presence of an under- 
lying MHC-restricted component of the response. In the five 
patients whose unstimulated PBMC  showed non-MHC- 
restricted killing of target cells expressing  env, the corre- 
sponding frequencies  of MHC-restricted env-specific CTL 
precursors in LDA were 0,  15, 17, 72, and 73/1@ PBMC. 
No correlation was observed between the presence of acti- 
vated MHC-restricted CTL and the magnitude of the CTL 
precursor response in LDA (Table 1). 
Discussion 
The frequency of MHC-restricted CTL precursors in 23 
HIV-l-infected patients ranged from 0 to 488/1@ PBMC, 
and the relative frequency against the different structural gene 
products varied from individual to individual. In cross-sectional 
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Figure 4.  The direct  cytotoxic 
response  in unstimulated PBMC 
was MHC restricted in a proportion 
of patients.  Unstimulated PBMC 
from three asymptomatic patients 
were assayed  for cytotoxicity against 
autologous and MHC-mismatched 
radiolabded target cells at different 
E/T ratios. (a) Patient 8; (b) patient 
7; (c) patient  5. analysis, the frequency of HIV-l-specific CTL precursors was 
reduced in patients with more severe CD4 lymphocyte deple- 
tion. In six of eight subjects who had very low HIV-l-specific 
CTL precursor frequencies,  the CTL precursor frequency 
against EBV was maintained. Activated MHC-restricted CTL 
in unstimulated PBMC were detected in a proportion of the 
patients, but no corrdation was observed with the magni- 
tude of the CTL precursor response in LDA. 
Virus-spedfic CTL precursors  have been  demonstrated 
during acute viral infections in humans, but for influenza- 
specific CTL after recovery from infection, the CTL activity 
progressively declines to undetectable levels (4). In contrast, 
the CTL response to persistent virus infections studied by 
LDA has shown that the frequency of virus-specific CTL 
precursors is maintained after initial infection, suggesting that 
during asymptomatic persistent infection the CTL response 
is subjected to a varying degree of restimulation in vivo and 
by inference may play a role in controlling viral replication. 
For instance, LDA has been used to examine the relative fre- 
quency of CTL precursors specific for viral antigens expressed 
at early and late stages of the virus replicative cycle during 
asymptomatic persistent infection with human cytomegalo- 
virus (HCMV) (12, 13). LDA can be used to derive quantita- 
tive estimates of CTL precursor frequency, but the absolute 
frequency must be interpreted with caution. Small differences 
in culture conditions in the LDA, the number of aliquots 
of responder cells derived from each well, and differences in 
the threshold used to determine cytotoxicity or noncytotox- 
icity can all influence the absolute frequency estimate.  The 
observed frequency estimate indicates the order of magnitude 
of the CTL response, and makes possible comparisons (be- 
tween different antigen specificities or between different time 
points) within the same experimental system. Previous studies 
have shown that part of the cytotoxic cellular response against 
lentiviruses is non-MHC restricted, particularly against target 
cells expressing the env gene product (18-20).  Therefore, in 
contrast to other recent studies in HIV and SIV (21, 22), 
we exploited a particular advantage of LDA in using split- 
well analysis to specifically exclude wells with non-MHC- 
restricted activity (NK activity) in every experiment, allowing 
the underlying MHC-restricted CTL precursor response to 
be quantified even in the presence of an NK response. Be- 
cause LDA examines a large number of short-term CTL clones 
derived directly from and representative of the original lym- 
phocyte population, LDA complements studies of the fine 
antigen specificity of long-term CTL clones where selection 
during prolonged in vitro culture may result in clones that 
are less representative  of the original population. 
CTL  precursor frequencies  against  EBV, HCMV,  and 
varicella-zoster  virus (VZV) in healthy laboratory workers 
have been previously reported, using the threshold of con- 
trol plus 3 SD in the analysis: EBV-specific CTL precursors 
(40-100/106 PBMC), HCMV-specific  CTL precursors  (20- 
80/106 PBMC), and VZV-specific CTL precursors (2-10/106 
PBMC) (12-14).  In comparison with these frequencies, the 
frequency of HIV-l-specific  CTL  precursors  was high in 
asymptomatic HIV-l-infected patients, supporting the findings 
of previous studies (7, 10). Furthermore, in the previous anal- 
yses of herpes virus-specific CTL precursors,  virus-infected 
cells were used as target cells, so that the observed responses 
reflect the aggregate CTL responses against cells expressing 
a constellation of different viral antigens, while the HIV-1- 
specific CTL responses in this study were directed against 
target cells expressing single HIV-1 gene products, either env, 
gag, or pol. Although in analyses of virus-specific CTL it 
is conventional to include whole virus-infected target cells, 
this presents difficulties in HIV-1 infection; the number of 
HIV-l-infected cells accessible from peripheral blood is low 
in asymptomatie HIV-1 infection, and target cells infected 
with laboratory strains of HIV-1 may not be representative 
of autologous viral strains. Work is in progress to develop 
an appropriate HIV-l-infected target cell system. 
The relative  frequency of CTL  precursors  against  the 
different gene products varies from one individual to another. 
One explanation for this may be differences in antigen pro- 
cessing and presentation by the different MHC alleles in the 
patients studied. In addition, particular CTL epitopes present 
in each patient's own virus population may not have been 
represented in the target ceUs we used, which expressed the 
gene products of the HIV-IIIB strain. Nevertheless, in most 
asymptomatic patients a CTL response could be detected 
against more than one viral gene product (presumably recog- 
nizing epitopes conserved between the patient's own viruses 
and HIV-IIIB). As reported recently by others, a particular 
CTL epitope within gag may undergo sequence variation in 
vivo that is no longer recognized by the CTL response (23), 
and sequence variation in CTL epitopes within env may im- 
pair CTL recognition (24). However, the fact that the CTL 
response recognizes more than one protein in the same pa- 
tient suggests that a change in single epitope would not neces- 
sarily abrogate the entire CTL response. 
In  the  cross-sectional  analysis of  HIV-l-specific  CTL 
precursors in this cohort of patients, the frequency of CTL 
precursors  detected in LDA was reduced in those who had 
severe CD4 + lymphocyte depletion. This might result from 
an inability to activate and detect in vitro the CTL precursors 
from patients with advanced HIV-1 infection. Possible mech- 
anisms might include impaired antigen presentation in vitro, 
lack of lymphokines essential for activation and differentia- 
tion of CTL (including lymphokines secreted by CD4 + T 
lymphocytes), the presence of suppressor ceUs, and failure of 
the target cell system to present particular antigenic variants 
that are recognized by the CTL responses of each individual. 
To determine whether there is a global impairment of the 
ability to generate a CTL response, or whether there might 
be a selective impairment of the HIV-l-specific CTL response, 
we carried out parallel experiments to determine the CTL 
precursor frequency against EBV in the same HIV-l-infected 
patients. The EBV-specific CTL response was maintained in 
six of eight patients whose HIV-l-specific CTL response was 
very low, suggesting that at least in some individuals there 
may be selective impairment of the HIV-l-specific  CTL re- 
sponse. A possible explanation for this might be differential 
requirements for CD4 + T cell help in the generation of the 
254  Quantitative Analysis of the HIV-l-specific Cytotoxic T Cell Response CTL responses against the two different viruses, HIV-1 and 
EBV (25). Alternatively,  there may be a genuine reduction 
in the numbers of HIV-l-specific CTL precursors as HIV-1 
infection progresses.  This raises  the question of clonal ex- 
haustion resulting from continuous stimulation of precursors, 
with inability to regenerate the memory cell pool because 
of impairment  of dendritic  cell function  (26). 
Little is known about the factors important in the terminal 
differentiation of human effector T cells. The direct cytotox- 
icity assays demonstrated the presence of circulating activated 
HIV-l-specific CTL (which did not require in vitro stimula- 
tion), but, as noted by others (10, 27), MHC-restricted HIV- 
1-specific CTL responses were detected in only a proportion 
of HIV-l-infected patients, while non-MHC-restricted cyto- 
toxicity was observed in several patients, particularly against 
targets expressing env. No correlation was observed here be- 
tween the magnitude of the CTL response detected in LDA 
and the direct unstimulated response against target cells ex- 
pressing  the same HIV-1 structural  gene product. 
The observed decline in CTL precursors specific for HIV-1 
as disease progresses raises interesting questions concerning 
the possible protective role of the CTL response. This is now 
being addressed by a longitudinal study of the HIV-l-specific 
CTL response in the infected patients of this cohort. Detailed 
study of lentivirus-specific CTL presents greater complexi- 
ties than those against other viruses, because the heteroge- 
neous virus population in vivo gives rise to a changing mix- 
ture of viral epitopes that evolves with time (28) and has the 
capacity to evade CTL recognition (23). Studies are now in 
progress to analyze the CTL response in relation to the viral 
variants that are present in each patient's own HIV-1 quasi- 
species. In addition, the approaches described here are appro- 
priate  to  study cellular  responses  to  vaccination  and  im- 
munotherapy. 
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